Telehealth mitigates COPD disease progression compared to standard of care: a randomized controlled crossover trial
- PMID: 33428219
- PMCID: PMC7986739
- DOI: 10.1111/joim.13230
Telehealth mitigates COPD disease progression compared to standard of care: a randomized controlled crossover trial
Abstract
Background: We showed excellent adherence and satisfaction with our telehealth care (TC) approach for COPD. Here, the results of a consecutive randomized controlled trial are presented.
Methods: Patients were randomly assigned to TC or standard care (SC). During TC, patients answered six daily questions online, and focused on the early recognition of exacerbations, in addition to SC.
Results: The mean increase in COPD assessment test (CAT) was 1.8 vs. 3.6 points/year in the TC and SC groups, respectively (P = 0.0015). Satisfaction with care (VAS) at baseline was 8.2; at the end of SC, 8.5 (P = 0.062); and after TC, 8.8 (P < 0.001). We detected significantly more moderate exacerbations during TC.
Conclusion: Whilst receiving TC, the slope of the CAT increase - an indicator of the naturally progressive course of COPD - was reduced by 50%. Satisfaction with care increased with TC. The higher number of detected moderate exacerbations probably indicates a higher diagnostic sensitivity than without TC.
Keywords: COPD; COPD assessment test; COPD exacerbation; telehealth.
© 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
Conflict of interest statement
The study was funded by Swisscom Health AG, SWICA Krankenversicherung AG, PneumRx GmbH, AstraZeneca AG and Boehringer Ingelheim Schweiz GmbH. None of these had any influence on design, conduct, interpretation or writing of the manuscript. Prof. Kohler reports personal fees from Bayer, Boehringer, Novartis, Astra and Mundipharma, all outside the submitted work, and grants and personal fees from Roche and GSK. Prof. Tamm reports grants from Vifor AG and Schwabe Pharma AG, all outside the submitted work. Prof. Stolz reports grants from AstraZeneca AG, Curetis AG and Boston Scientific and personal fees from AstraZeneca AG, Novartis AG, GSK AG, Roche AG, Zambon, Pfizer, Schwabe Pharma AG and Vifor AG, all outside the submitted work.
References
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical